Hexima News and Investor Updates
Hexima’s Chief Executive Officer, Dr Nicole van der Weerden and Chief Science Officer, Professor Marilyn Anderson, presented Hexima’s Plant Defensin technology at the International Society for Human and Animal Mycology (ISHAM) congress in Amsterdam this week. The...
Hexima Limited is pleased to announce today that it has completed enrolment for the dose escalation stage of its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections. Hexima’s CEO Dr Nicole van der Weerden said “The HXP124 clinical trial is...
Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.
Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.”
Click on title to read more.
Hexima is now recruiting patients for its fungal nail infection clinical trial. Interested in volunteering? Find out more at www.toenailstudy.com.au.
See Hexima's Chief Science Officer, Prof Marilyn Anderson, talking about our new treatment for toenail fungus in this new video by the Australian Academy of Science. View video here
Presentations and Results from the 2017 Hexima Limited Annual General Meeting held 21st November 2017
Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.
Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval for our first clinical trial is a major milestone for Hexima. It is the culmination of the last three years of work to generate the required non-clinical data including preclinical safety/toxicology, efficacy testing and manufacture, formulation and stability of HXP124. The ethics committee has reviewed this data, along with our clinical study design, and granted us permission to test this molecule on human patients for the first time. This is a critical step forward in the development of HXP124 as a treatment for fungal nail infections and we are very excited to begin this next phase of development.”
NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited ABN 64 079 319 314 (“Company”) will be held at KPMG, Level 36, Tower 2, Collins Square, 727 Collins Street, Melbourne, Victoria on Tuesday 21 November 2017 at 11am.
Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.
Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).